Trial Profile
Phase II Study on Sitagliptin -Assessment of Glucose-Lowering Effects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 12 Feb 2009 Actual end date (Oct 2006) added as reported by ClinicalTrials.gov.
- 03 Oct 2008 New trial record.